<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIHYDROERGOTAMINE MESYLATE- dihydroergotamine mesylate spray </strong><br>Oceanside Pharmaceuticals<br></p></div>
<h1>Dihydroergotamine Mesylate, USP<br>Nasal Spray</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">The solution used in dihydroergotamine mesylate, USP nasal spray (4 mg/mL) is intended for intranasal use and must not be injected.</span></p>
<p>Rx Only</p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First">Serious and/or life-threatening <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span> has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities is increased. Hence, concomitant use of these medications is contraindicated.</p>
<p>(See also <span class="Italics"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span> and <span class="Italics"><a href="#WARNINGS">WARNINGS</a></span> section)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dihydroergotamine mesylate, USP is ergotamine hydrogenated in the 9,10 position as the mesylate salt. Dihydroergotamine mesylate, USP is known chemically as ergotaman-3', 6', 18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'- (phenylmethyl)-, (5'α)-, monomethanesulfonate. Its molecular weight is 679.80 and its empirical formula is C<span class="Sub">33</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">5</span>•CH<span class="Sub">4</span>O<span class="Sub">3</span>S. </p>
<p>The chemical structure is:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc&amp;name=migranal-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Dihydroergotamine mesylate, USP nasal spray is provided for intranasal administration as a clear, colorless to faintly yellow solution in an amber glass vial containing:</p>
<table width="60%">
<col align="left" valign="middle" width="75%">
<col align="right" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">dihydroergotamine mesylate, USP</td>
<td align="right">4.0 mg</td>
</tr>
<tr>
<td align="left">caffeine, anhydrous, USP</td>
<td align="right">10.0 mg</td>
</tr>
<tr>
<td align="left">dextrose, anhydrous, USP</td>
<td align="right">50.0 mg</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>, USP</td>
<td align="right">qs</td>
</tr>
<tr class="Botrule Last">
<td align="left">purified water, USP</td>
<td align="right">qs 1.0 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Dihydroergotamine binds with high affinity to 5-HT<span class="Sub">1Dα</span> and 5-HT<span class="Sub">1Dβ</span> receptors. It also binds with high affinity to serotonin 5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">2A</span>, and 5-HT<span class="Sub">2C</span> receptors, noradrenaline α<span class="Sub">2A</span>, α<span class="Sub">2B</span> and α1 receptors, and dopamine D<span class="Sub">2L</span> and D<span class="Sub">3</span> receptors.</p>
<p>The therapeutic activity of dihydroergotamine in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> is generally attributed to the agonist effect at 5-HT<span class="Sub">1D</span> receptors. Two current theories have been proposed to explain the efficacy of 5-HT<span class="Sub">1D</span> receptor agonists in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. One theory suggests that activation of 5-HT<span class="Sub">1D</span> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, which correlates with the relief of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. The alternative hypothesis suggests that activation of 5-HT<span class="Sub">1D</span> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. In addition, dihydroergotamine possesses oxytocic properties. <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Dihydroergotamine mesylate is poorly bioavailable following oral administration. Following intranasal administration, however, the mean bioavailability of dihydroergotamine mesylate is 32% relative to the injectable administration. Absorption is variable, probably reflecting both intersubject differences of absorption and the technique used for self-administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Dihydroergotamine mesylate is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8'-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT receptors and demonstrates equivalent potency in several venoconstrictor activity models, <span class="Italics">in vivo</span> and  <span class="Italics">in vitro</span>. The other metabolites, i.e., dihydrolysergic acid, dihydrolysergic amide and a metabolite formed by oxidative opening of the proline ring are of minor importance. Following nasal administration, total metabolites represent only 20%-30% of plasma AUC. The systemic clearance of dihydroergotamine mesylate following I.V. and I.M. administration is 1.5 L/min. Quantitative pharmacokinetic characterization of the four metabolites has not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">The major excretory route of dihydroergotamine is via the bile in the feces. After intranasal administration the urinary recovery of parent drug amounts to about 2% of the administered dose compared to 6% after I.M. administration. The total body clearance is 1.5 L/min which reflects mainly hepatic clearance. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration. The decline of  plasma dihydroergotamine is biphasic with a terminal half-life of about 10 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5"></a><p></p>
<h3>Subpopulations</h3>
<p class="First">No studies have been conducted on the effect of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, gender, race, or ethnicity on dihydroergotamine pharmacokinetics. Dihydroergotamine mesylate, USP nasal spray is contraindicated in patients with severely impaired hepatic or renal function. <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.6"></a><p></p>
<h3>Interactions</h3>
<p class="First">The pharmacokinetics of dihydroergotamine did not appear to be significantly affected by the concomitant use of a local vasoconstrictor (e.g., fenoxazoline).</p>
<p>Multiple oral doses of the β-adrenoceptor antagonist propranolol, used for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis, had no significant influence on the Cmax, Tmax or AUC of dihydroergotamine doses up to 4 mg. <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interactions</span> have been reported in patients treated orally with other ergot alkaloids (e.g., increased levels of ergotamine) and macrolide antibiotics, principally troleandomycin, presumably due to inhibition of cytochrome P450 3A metabolism of the alkaloids by troleandomycin. Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g. ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span>. No  <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>Clinical Trials</h1>
<p class="First">The efficacy of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> was evaluated in four randomized, double blind, placebo controlled studies in the U.S. The patient population for the trials was predominantly female (87%) and Caucasian (95%) with a mean age of 39 years (range 18 to 65 years). Patients treated a single moderate to severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> with a single dose of study medication and assessed <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> severity over the 24 hours following treatment. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was determined 0.5, 1, 2, 3 and 4 hours after dosing and was defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In studies 1 and 2, a four-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scale was utilized; in studies 3 and 4, a five-point scale was used that included both <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response and restoration of function for "severe" or "incapacitating" <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, a less clear endpoint. Although rescue medication was allowed in all four studies, patients were instructed not to use them during the four hour observation period. In studies 3 and 4, a total dose of 2 mg was compared to placebo. In studies 1 and 2, doses of 2 and 3 mg were evaluated, and showed no advantage of the higher dose for a single treatment. In all studies, patients received a regimen consisting of 0.5 mg in each nostril, repeated in 15 minutes (and again in another 15 minutes for the 3 mg dose in studies 1 and 2).</p>
<p>The percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 4 hours after treatment was significantly greater in patients receiving 2 mg doses of Migranal<span class="Sup">®</span>  (dihydroergotamine mesylate, USP) Nasal Spray compared to those receiving placebo in 3 of the 4 studies (see <a href="#t1">Tables 1 </a><a href="#t2">&amp; 2</a> and <a href="#fig1">Figures 1 </a><a href="#fig2">&amp; 2</a>).</p>
<a name="t1"></a><table width="80%">
<caption><span>Table 1: Studies 1 and 2: Percentage of patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> 2 and 4 hours following a single treatment of study medication [Migranal<span class="Sup">®</span>  (dihydroergotamine mesylate, USP) Nasal Spray or Placebo]</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left"></th>
<th align="left">N</th>
<th align="left">2 hours</th>
<th align="left">4 hours</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was based on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity as interpreted by the patient using a four-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scale.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p value &lt; 0.001</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>p value &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Study 1</td>
<td align="left">Migranal<span class="Sup">®</span>
</td>
<td align="left">105 </td>
<td align="left">61%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="left"> 70%<a href="#footnote-2" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="left">Placebo </td>
<td align="left">98</td>
<td align="left">23%</td>
<td align="left"> 28%</td>
</tr>
<tr>
<td align="left">Study 2</td>
<td align="left">Migranal<span class="Sup">®</span>
</td>
<td align="left">103</td>
<td align="left">47%</td>
<td align="left">   56%<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="left">Placebo</td>
<td align="left">102</td>
<td align="left">33%</td>
<td align="left">35%</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table width="80%">
<caption><span>Table 2: Studies 3 and 4: Percentage of patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> 2 and 4 hours following a single treatment of study medication [Migranal<span class="Sup">®</span>  (dihydroergotamine mesylate, USP) Nasal Spray or Placebo]</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left"></th>
<th align="left">N</th>
<th align="left">2 hours</th>
<th align="left">4 hours</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was evaluated on a five-point scale that included both <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response and restoration of function for "severe" or "incapacitating" <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>p value &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Study 3</td>
<td align="left">Migranal<span class="Sup">®</span>
</td>
<td align="left">50</td>
<td align="left">32%</td>
<td align="left">   48%<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="left">Placebo </td>
<td align="left">50</td>
<td align="left">20%</td>
<td align="left">   22%</td>
</tr>
<tr>
<td align="left">Study 4</td>
<td align="left">Migranal<span class="Sup">®</span>
</td>
<td align="left">47</td>
<td align="left">30%</td>
<td align="left">47%</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="left">Placebo</td>
<td align="left">50</td>
<td align="left">20%</td>
<td align="left">30%</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Comparisons of drug performance based upon results obtained in different clinical trials are never reliable. Because studies are conducted at different times, with different samples of patients, by different investigators, employing different criteria and/or different interpretations of the same criteria, under different conditions (dose, dosing regimen, etc.), quantitative estimates of treatment response and the timing of response may be expected to vary considerably from study to study.</span></p>
<p>The Kaplan-Meier plots below (Figures 1 &amp; 2) provides an estimate of the probability that a patient will have responded to a single 2 mg dose of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray as a function of the time elapsed since initiation of treatment.</p>
<div class="Figure">
<a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc&amp;name=migranal-02.jpg">
</div>
<p>* The figure shows the probability over time of obtaining a response following treatment with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was based on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity as interpreted by the patient using a four-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scale. Patients not achieving response within 4 hours were censored to 4 hours.</p>
<div class="Figure">
<a name="fig2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc&amp;name=migranal-03.jpg">
</div>
<p>* The figure shows the probability over time of obtaining a response following treatment with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response was evaluated on a five-point scale that confounded <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response and restoration of function for "severe" or "incapacitating" <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Patients not achieving response within 4 hours were censored to 4 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline, there was a lower incidence of these symptoms at 2 and 4 hours following administration of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray compared to placebo.</p>
<p>Patients were not allowed to use additional treatments for eight hours prior to study medication dosing and during the four hour  observation period following study treatment. Following the 4 hour observation period, patients were allowed to use additional treatments. For all studies, the estimated probability of patients using additional treatments for their <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> over the 24 hours following the single 2 mg dose of study treatment is summarized in Figure 3 below.</p>
<div class="Figure">
<a name="fig3"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc&amp;name=migranal-04.jpg">
</div>
<p>* Kaplan-Meier plot based on data obtained from all studies with patients not using additional treatments censored to 24 hours. All patients received a single treatment of study medication for their <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. The plot also includes patients who had no response to the initial dose.</p>
<p>Neither age nor sex appear to effect the patient's  response to Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray. While patients with menstrual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>, and <span class="product-label-link" type="condition" conceptid="378735" conceptname="Migraine without aura">migraine without aura</span> by medical history were included in the clinical evaluation of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray, patients were not required to report the specific type of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> treated with study medication. Thus, neither the effect of menses on <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> nor the presence or the absence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> were assessed. The racial distribution of patients was insufficient to determine the effect of race on the efficacy of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Dihydroergotamine mesylate, USP nasal spray is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>.</p>
<p>Dihydroergotamine mesylate, USP nasal spray is not intended for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or for the management of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">There have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> that led to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. The use of potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (See <a href="#CYP">WARNINGS: CYP 3A4 Inhibitors</a>).</span></p>
<p><span class="Bold">Dihydroergotamine mesylate, USP nasal spray should not be given to patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>  (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or to patients who have clinical symptoms or findings consistent with coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>  including Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>. (See <a href="#WARNINGS">WARNINGS</a>)</span></p>
<p><span class="Bold">Because dihydroergotamine mesylate, USP nasal spray may increase blood pressure, it should not be given to patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</span></p>
<p><span class="Bold">Dihydroergotamine mesylate, USP nasal spray, 5-HT1 agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other.</span></p>
<p><span class="Bold">Dihydroergotamine mesylate, USP nasal spray should not be administered to patients with hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</span></p>
<p>In addition to those conditions mentioned above, dihydroergotamine mesylate, USP nasal spray is also contraindicated in patients with known peripheral arterial disease, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, following vascular surgery, and severely impaired hepatic or renal function.</p>
<p>Dihydroergotamine mesylate, USP nasal spray may cause fetal harm when administered to a pregnant woman. Dihydroergotamine possesses oxytocic properties and, therefore, should not be administered during pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>There are no adequate studies of dihydroergotamine in human pregnancy, but developmental toxicity has been demonstrated in experimental animals. In embryofetal development studies of dihydroergotamine mesylate nasal spray, intranasal administration to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weights and/or skeletal ossification at doses of 0.16 mg/day (associated with maternal plasma dihydroergotamine exposures [AUC] approximately 0.4 -1.2 times the exposures in humans receiving the MRDD of 4 mg) or greater. A no effect level for embryo-fetal toxicity was not established in rats. Delayed skeletal ossification was also noted in rabbit fetuses following intranasal administration of 3.6 mg/day (maternal exposures approximately 7 times human exposures at the MRDD) during organogenesis. A no effect level was seen at 1.2 mg/day (maternal exposures approximately 2.5 times human exposures at the MRDD). When dihydroergotamine mesylate nasal spray was administered intranasally to female rats during pregnancy and lactation, decreased body weights and impaired reproductive function (decreased mating indices) were observed in the offspring at doses of 0.16 mg/day or greater. A no effect level was not established. Effects on development occurred at doses below those that produced evidence of significant maternal toxicity in these studies. Dihydroergotamine-induced <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span> has been attributed to reduced uteroplacental blood flow resulting from prolonged <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of the uterine vessels and/or increased myometrial tone.</p>
<p>Dihydroergotamine mesylate, USP nasal spray is contraindicated in patients who have previously shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ergot alkaloids.</p>
<p>Dihydroergotamine mesylate should not be used by nursing mothers. (See <a href="#PRECAUTIONS">PRECAUTIONS</a>)</p>
<p>Dihydroergotamine mesylate should not be used with peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Dihydroergotamine mesylate, USP nasal spray should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> has been established.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="CYP"></a><a name="section-7.1"></a><p></p>
<h2>CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors)</h2>
<p class="First"><span class="Bold">There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> that led to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. The use of potent CYP 3A4 inhibitors with dihydroergotamine should therefore be avoided <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span>. Examples of some of the more potent CYP 3A4 inhibitors include: antifungals ketoconazole and itraconazole, the protease inhibitors ritonavir, nelfinavir, and indinavir, and macrolide antibiotics erythromycin, clarithromycin, and troleandomycin. Other less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should  consider the effects on CYP3A4 of other agents being considered for concomitant use with dihydroergotamine.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Fibrotic"></a><a name="section-7.2"></a><p></p>
<h2>Fibrotic Complications</h2>
<p class="First">There have been reports of pleural and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> in patients following prolonged daily use of injectable dihydroergotamine mesylate. Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Rare cases have also been reported in association with the use of injectable dihydroergotamine mesylate; however, in those cases, patients also received drugs known to be associated with cardiac valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p>Administration of dihydroergotamine mesylate, USP nasal spray, should not exceed the dosing guidelines and should not be used for chronic daily administration (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</h2>
<p class="First"><span class="Bold">Dihydroergotamine mesylate, USP nasal spray should not be used by patients with documented ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span> It is strongly recommended that dihydroergotamine mesylate, USP nasal spray not be given to patients in whom unrecognized <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) is predicted by the presence of risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, smoker, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, strong family history of CAD, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest, at best. If, during the cardiovascular evaluation, the patient's medical history or electrocardiographic investigations reveal findings indicative of or consistent with coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, dihydroergotamine mesylate, USP nasal spray should not be administered. <span class="Italics">(See  <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></span></p>
<p><span class="Bold">For patients with risk factors predictive of CAD who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of dihydroergotamine mesylate, USP nasal sprayy take place in the setting of a physician's office or similar medically staffed and equipped facility unless the patient has previously received dihydroergotamine mesylate. Because <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following dihydroergotamine mesylate, USP nasal spray, in these patients with risk factors.</span></p>
<p><span class="Bold">It is recommended that patients who are intermittent long-term users of dihydroergotamine mesylate, USP nasal spray and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use dihydroergotamine mesylate, USP nasal spray.</span></p>
<p><span class="Bold">The systematic approach described above is currently recommended as a method to identify patients in whom dihydroergotamine mesylate, USP nasal spray may be used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with an acceptable margin of cardiovascular safety.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Cardiac Events and Fatalities</h2>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported in patients using dihydroergotamine mesylate, USP nasal spray. However, the potential for adverse cardiac events exists. Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, life-threatening disturbances of cardiac rhythm, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported to have occurred following the administration of dihydroergotamine mesylate injection (e.g., D.H.E. 45<span class="Sup">®</span>  Injection). Considering the extent of use of dihydroergotamine mesylate in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the incidence of these events is extremely low.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Drug-Associated Cerebrovascular Events and Fatalities</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and other cerebrovascular events have been reported in patients treated with D.H.E. 45<span class="Sup">®</span>  Injection; and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the D.H.E. 45<span class="Sup">®</span>  Injection having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. It should be noted that patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Related Events</h2>
<p class="First">Dihydroergotamine mesylate, USP nasal spray, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. Myocardial and peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> have been reported with dihydroergotamine mesylate, USP nasal spray.</p>
<p>Dihydroergotamine mesylate, USP nasal spray associated vasospastic phenomena may also cause <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the digits. In patients with compromised circulation, persistent <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> may result in <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, dihydroergotamine mesylate, USP nasal spray should be discontinued immediately if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>Increase in Blood Pressure</h2>
<p class="First">Significant elevation in blood pressure has been reported on rare occasions in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray and dihydroergotamine mesylate injection. Dihydroergotamine mesylate, USP nasal spray is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>. <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></p>
<p>An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5HT1 agonist in a study evaluating subjects undergoing cardiac catheterization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>Local Irritation</h2>
<p class="First">Approximately 30% of patients using Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray (compared to 9% of placebo patients) have reported irritation in the nose, throat, and/or disturbances in taste. Irritative symptoms include congestion, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, dryness, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, discharge, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or soreness. The symptoms were predominantly mild to moderate in severity and transient. In approximately 70% of the above mentioned cases, the symptoms resolved within four hours after dosing with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray. Examinations of the nose and throat in a small subset (N = 66) of study participants treated for up to 36 months (range 1-36 months) did not reveal any clinically noticeable injury. Other than this limited number of patients, the consequences of extended and repeated use of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray on the nasal and/or respiratory mucosa have not been systematically evaluated in patients.</p>
<p>Nasal tissue in animals treated with dihydroergotamine mesylate daily at nasal cavity surface area exposures (in mg/mm<span class="Sup">2</span>) that were equal to or less than those achieved in humans receiving the maximum recommended daily dose of 0.08 mg/kg/day showed mild mucosal irritation characterized by mucous cell and transitional cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">squamous cell metaplasia</span>. Changes in rat nasal mucosa at 64 weeks were less severe than at 13 weeks. Local effects on respiratory tissue after chronic intranasal dosing in animals have not been evaluated.</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Dihydroergotamine mesylate, USP nasal spray may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>; patients who experience signs or symptoms suggestive of angina following its administration should, therefore, be evaluated for the presence of CAD or a predisposition to <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome following the use of any 5-HT agonist are candidates for further evaluation. (See <a href="#WARNINGS">WARNINGS</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>Fibrotic Complications</h3>
<p class="First"><span class="Italics">see <a href="#Fibrotic">WARNINGS: Fibrotic Complications</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The text of a patient information sheet is printed at the end of this insert. To assure safe and effective use of dihydroergotamine mesylate, USP nasal spray, the information and instructions provided in the patient information sheet should be discussed with patients.</p>
<p>Once the nasal spray applicator has been prepared, it should be discarded (with any remaining drug) after 8 hours.</p>
<p>Patients should be advised to report to the physician immediately any of the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in the fingers and toes, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> in the arms and legs, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest, temporary speeding or slowing of the heart rate, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p>Prior to the initial use of the product by a patient, the prescriber should take steps to ensure that the patient understands how to use the product as provided. (See Patient Information Sheet and product packaging).</p>
<p>Administration of dihydroergotamine mesylate, USP nasal spray, should not exceed the dosing guidelines and should not be used for chronic daily administration (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<h3>Vasoconstrictors</h3>
<p class="First">Dihydroergotamine mesylate, USP nasal spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<h3>Sumatriptan</h3>
<p class="First">Sumatriptan has been reported to cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, and its effect could be additive with dihydroergotamine mesylate, USP nasal spray. Sumatriptan and dihydroergotamine mesylate, USP nasal spray should not be taken within 24 hours of each other. <span class="Italics">(See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<h3>Beta Blockers</h3>
<p class="First">Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate, USP nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.4"></a><p></p>
<h3>Nicotine</h3>
<p class="First">Nicotine may provoke <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> in some patients, predisposing to a greater ischemic response to ergot therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.5"></a><p></p>
<h3>CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors)</h3>
<p class="First"><span class="Italics">See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a> and <a href="#WARNINGS">WARNINGS.</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.6"></a><p></p>
<h3>SSRI's</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> have been reported rarely when 5HT<span class="Sub">1</span> agonists have been coadministered with SSRI's (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline). There have been no reported cases from spontaneous reports of drug interaction between SSRI's and dihydroergotamine mesylate, USP nasal spray or D.H.E. 45<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.7"></a><p></p>
<h3>Oral Contraceptives</h3>
<p class="First">The effect of oral contraceptives on the pharmacokinetics of dihydroergotamine mesylate, USP nasal spray has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Assessment of the carcinogenic potential of dihydroergotamine mesylate in mice and rats is ongoing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">Dihydroergotamine mesylate was clastogenic in two <span class="Italics">in vitro</span> chromosomal aberration assays, the V79 Chinese hamster cell assay with metabolic activation and the cultured human peripheral blood lymphocyte assay. There was no evidence of mutagenic potential when dihydroergotamine mesylate was tested in the presence or absence of metabolic activation in two gene mutation assays (the Ames test and the <span class="Italics">in vitro</span> mammalian Chinese hamster V79/HGPRT assay) and in an assay for DNA damage (the rat hepatocyte unscheduled DNA synthesis test). Dihydroergotamine was not clastogenic in the <span class="Italics">in vivo</span> mouse and hamster micronucleus tests.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">There was no evidence of impairment of fertility in rats given intranasal doses of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray up to 1.6 mg/day (associated with mean plasma dihydroergotamine mesylate exposures [AUC] approximately 9 to 11 times those in humans receiving the MRDD of 4 mg).</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<h3>Pregnancy Category X</h3>
<p class="First"><span class="Italics">See <a href="http://CONTRAINDICATIONS">CONTRAINDICATIONS.</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ergot drugs are known to inhibit prolactin. It is likely that dihydroergotamine mesylate, USP nasal spray is excreted in human milk, but there are no data on the concentration of dihydroergotamine in human milk. It is known that ergotamine is excreted in breast milk and may cause <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, weak pulse, and unstable blood pressure in nursing infants. Because of the potential for these serious adverse events in nursing infants exposed to dihydroergotamine mesylate, USP nasal spray, nursing should not be undertaken with the use of dihydroergotamine mesylate, USP nasal spray. <span class="Italics">(See <a href="http://CONTRAINDICATIONS">CONTRAINDICATIONS)</a></span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.8"></a><p></p>
<h2>Use in the Elderly</h2>
<p class="First">There is no information about the safety and effectiveness of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray in this population because patients over age 65 were excluded from the controlled clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">During clinical studies and the foreign postmarketing experience with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray there have been no fatalities due to cardiac events.</span></p>
<p>Serious cardiac events, including some that have been fatal, have occurred following use of the parenteral form of dihydroergotamine mesylate (D.H.E. 45<span class="Sup">®</span> Injection), but are extremely rare. Events reported have included coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. (See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>, <a href="#WARNINGS">WARNINGS</a>, and <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
<p>Fibrotic complications have been reported in association with long term use of injectable dihydroergotamine mesylate (see <a href="#Fibrotic">WARNINGS: Fibrotic Complications</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Incidence in Controlled Clinical Trials</h2>
<p class="First">Of the 1,796 patients and subjects treated with Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray doses 2 mg or less in U.S. and foreign clinical studies, 26 (1.4%) discontinued because of adverse events. The adverse events associated with discontinuation were, in decreasing order of frequency: <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> 13, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 2, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> 2, and one each due to <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweats</span>, accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, elective surgery, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>.</p>
<p>The most commonly reported adverse events associated with the use of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray during placebo-controlled, double-blind studies for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> and not reported at an equal incidence by placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, altered sense of taste, <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.</p>
<p>Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray was generally well tolerated. In most instances these events were transient and self-limited and did not result in patient discontinuation from a study. The following table summarizes the incidence rates of adverse events reported by at least 1% of patients who received Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> during placebo-controlled, double-blind clinical studies and were more frequent than in those patients receiving placebo.</p>
<table width="80%">
<caption><span>Table 3: Adverse events reported by at least 1% of the Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray treated patients and occurred more frequently than in the placebo-group in the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> placebo-controlled trials</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Migranal<span class="Sup">®</span><br>N=597</th>
<th align="center">Placebo<br>N=631</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Respiratory System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </td>
<td align="center">26% </td>
<td align="center">7%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center">3% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td align="center">1% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Gastrointestinal System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center">10% </td>
<td align="center">4%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center">4% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center">2% </td>
<td align="center">&lt;1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Special Senses, Other</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    Altered Sense of Taste </td>
<td align="center">8% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Application Site</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span> </td>
<td align="center">6% </td>
<td align="center">2%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Central and Peripheral Nervous System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center">4% </td>
<td align="center">2%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </td>
<td align="center">3% </td>
<td align="center">2%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span> </td>
<td align="center">2% </td>
<td align="center">2%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole, General</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flashes</span> </td>
<td align="center">1% </td>
<td align="center">&lt;1%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </td>
<td align="center">1% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td align="center">1% </td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Autonomic Nervous System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Mouth Dry</span> </td>
<td align="center">1% </td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">Musculoskeletal System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">    <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Stiffness</span> </td>
<td align="center">1% </td>
<td align="center">&lt;1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Other Adverse Events During Clinical Trials</h2>
<p class="First">In the paragraphs that follow, the frequencies of less commonly reported adverse clinical events are presented. Because the reports include events observed in open and uncontrolled studies, the role of Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, etc., limit the value of the quantitative frequency estimates provided. Event frequencies are calculated as the number of patients who used Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray in placebo-controlled trials and reported an event divided by the total number of patients (n=1796) exposed to Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray. All reported events are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; and rare adverse events are those occurring in fewer than 1/1,000 patients.</p>
<p><span class="Bold Italics">Skin and Appendages: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin; Rare: <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">papular rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, herpes simplex.</p>
<p><span class="Bold Italics">Musculoskeletal: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>; Rare: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>.</p>
<p><span class="Bold Italics">Central and Peripheral Nervous System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; Rare: speech disorder, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, aggravated <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p>Autonomic Nervous System: <span class="Italics">Infrequent: </span> increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p><span class="Bold Italics">Special Senses: </span><span class="Italics">Infrequent: </span>sense of smell altered, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, abnormal <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
<p><span class="Bold Italics">Psychiatric: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">concentration impaired</span>; Rare: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold Italics">Gastrointestinal: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>; Rare: <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="134681" conceptname="Diffuse spasm of esophagus">esophagospasm</span>.</p>
<p><span class="Bold Italics">Cardiovascular: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="Italics">Rare:  </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, angina.</p>
<p><span class="Bold Italics">Respiratory System: </span><span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>; Rare: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4330445" conceptname="Pleuritic pain">pleural pain</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Bold Italics">Urinary System: </span><span class="Italics">Infrequent: </span>increased <span class="product-label-link" type="condition" conceptid="200843" conceptname="Finding of frequency of urination">frequency of micturition</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>.</p>
<p><span class="Bold Italics">Reproductive, Female: </span><span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammation</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
<p><span class="Bold Italics">Body as a Whole -</span> General: <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>; Rare: flu-like symptoms, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="40481303" conceptname="Aphonia">loss of voice</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>.</p>
<p><span class="Bold Italics">Application Site: </span><span class="Italics">Infrequent: </span>local anesthesia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Post-introduction Reports</h2>
<p class="First">Voluntary reports of adverse events temporally associated with dihydroergotamine products used in the management of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> that have been received since the introduction of the injectable formulation are included in this section save for those already listed above. Because of their source (open and uncontrolled clinical use), whether or not events reported in association with the use of dihydroergotamine are causally related to it cannot be determined. There have been reports of pleural and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> in patients following prolonged daily use of injectable dihydroergotamine mesylate. Dihydroergotamine mesylate, USP nasal spray is not recommended for prolonged daily use. (See <a href="#DA">DOSAGE AND ADMINISTRATION</a>)</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Currently available data have not demonstrated drug abuse or psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> with dihydroergotamine. However, cases of drug abuse and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in patients on other forms of ergot therapy have been reported. Thus, due to the chronicity of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>, it is imperative that patients be advised not to exceed recommended dosages.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">To date, there have been no reports of acute overdosage with this drug. Due to the risk of vascular spasm, exceeding the recommended dosages of dihydroergotamine mesylate, USP nasal spray is to be avoided. </p>
<p>Excessive doses of dihydroergotamine may result in peripheral signs and symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>. Treatment includes discontinuance of the drug, local application of warmth to the affected area, the administration of vasodilators, and nursing care to prevent tissue damage.</p>
<p>In general, the symptoms of an acute dihydroergotamine mesylate, USP nasal spray <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are similar to those of an ergotamine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, although there is less pronounced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with dihydroergotamine mesylate, USP nasal spray. The symptoms of an ergotamine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the extremities associated with diminished or absent peripheral pulses; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; an increase and/or decrease in blood pressure, usually in that order; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; and/or some degree of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>In laboratory animals, significant lethality occurs when dihydroergotamine is given at I.V. doses of 44 mg/kg in mice, 130 mg/kg in rats, and 37 mg/kg in rabbits.</p>
<p>Up-to-date information about the treatment of overdosage can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Poison Control Centers are listed in the Physicians' Desk Reference<span class="Sup">®</span> (PDR).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The solution used in dihydroergotamine mesylate, USP nasal spray (4 mg/mL) is intended for intranasal use and must not be injected.</span></p>
<p>In clinical trials, Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray has been effective for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>. One spray (0.5 mg) of dihydroergotamine mesylate, USP nasal spray should be administered in each nostril. Fifteen minutes later, an additional one spray (0.5 mg) of dihydroergotamine mesylate, USP nasal spray should be administered in each nostril, for a total dosage of four sprays (2.0 mg) of dihydroergotamine mesylate, USP nasal spray. Studies have shown no additional benefit from acute doses greater than 2.0 mg for a single <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> administration. The safety of doses greater than 3.0 mg in a 24 hour period and 4.0 mg in a 7 day period has  not been established.</p>
<p>Dihydroergotamine mesylate, USP nasal spray, should not be used for chronic daily administration.</p>
<p><span class="Bold Italics">Prior to administration, the pump must be primed (i.e., squeeze 4 times) before use. (See administration instructions).</span></p>
<p><span class="Bold">Once the nasal spray applicator has been prepared, it should be discarded (with any remaining drug in opened vial) after 8 hours.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Dihydroergotamine mesylate, USP nasal spray is available (as a clear, colorless to faintly yellow solution) in 3.5 mL amber glass vials containing 4 mg of dihydroergotamine mesylate, USP. Dihydroergotamine mesylate, USP nasal spray is provided as a package of 8 units, administration instruction sheet, and one package insert. Each unit consists of one vial and one sprayer. (NDC 68682-357-10)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First">Store below 25°C (77°F). Do not refrigerate or freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>Patient Information</h1>
<p class="First"><span class="Bold Italics">Information for the Patient</span></p>
<p>Dihydroergotamine mesylate, USP nasal spray.</p>
<p>The solution used in dihydroergotamine mesylate, USP nasal spray (4 mg/mL) is intended for intranasal use and must not be injected.</p>
<p>Please read this information carefully before using your dihydroergotamine mesylate, USP nasal spray for the first time. Keep this information handy for future reference. This leaflet does not contain all of the information on dihydroergotamine mesylate, USP nasal spray. Your pharmacist and/or health care provider can provide more detailed information.</p>
<p>Dihydroergotamine mesylate, USP nasal spray has been evaluated in a limited number of patients long term (e.g., 1 year or longer).</p>
<p><span class="Bold Italics">Purpose of your Medication</span></p>
<p>Dihydroergotamine mesylate, USP nasal spray is intended to treat an active <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Do not try to use it to prevent a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> if you have no symptoms. Do not use it to treat common <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> or a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that is not at all typical of your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Administration of dihydroergotamine mesylate, USP nasal spray, should not exceed the dosing guidelines and should not be used for chronic daily administration. There have been reports of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> (stiffening) in the lung or kidney areas in patients following prolonged daily use of injectable dihydroergotamine mesylate. Rarely, prolonged daily use of other ergot alkaloid drugs (the class of drugs to which dihydroergotamine mesylate, USP nasal spray belongs) has been associated with heart valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Rare cases have also been reported in association with the use of injectable dihydroergotamine mesylate; however, in those cases, patients also received drugs known to be associated with heart valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p><span class="Bold">Do not use dihydroergotamine mesylate, USP nasal spray if you:</span></p>
<ul>
<li>Are pregnant or nursing.</li>
<li>have any disease affecting your heart, arteries, or circulation.</li>
<li>are taking certain anti-HIV medications (protease inhibitors)</li>
<li>are taking a macrolide antibiotic such as troleandomycin, clarithromycin or erythromycin.</li>
</ul>
<p><span class="Bold">Important questions to consider before using dihydroergotamine mesylate, USP nasal spray</span></p>
<p>Please answer the following questions before you use your dihydroergotamine mesylate, USP nasal spray. If you answer YES to any of these questions or are unsure of the answer, you should talk to your doctor before using dihydroergotamine mesylate, USP nasal spray.</p>
<ul>
<li>Do you have high blood pressure?</li>
<li>Do you have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, heart disease, or have you had any surgery on your heart arteries?</li>
<li>Do you have risk factors for heart disease (such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, smoking, strong family history of heart disease, or are you postmenopausal or a male over 40)?</li>
<li>Do you have any problems with blood circulation in your arms or legs, fingers, or toes?</li>
<li>Are you pregnant? Do you think you might be pregnant? Are you trying to become pregnant? Are you sexually active and not using birth control? Are you breast feeding?</li>
<li>Have you ever had to stop taking this or any other medication because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bad reaction?</li>
<li>Are you taking any other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> medications, erythromycin or other antibiotics, or medications for blood pressure prescribed by your doctor, or other medicines obtained from your drugstore without a doctor's prescription?</li>
<li>Do you smoke?</li>
<li>Have you had, or do you have, any disease of the liver or kidney?</li>
<li>Is this <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> different from your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks?</li>
<li>Are you using dihydroergotamine mesylate, USP nasal spray or other dihydroergotamine mesylate containing drugs on a daily basis?</li>
<li>Are you taking a protease inhibitor for HIV therapy?</li>
<li>Are you taking a macrolide class of antibiotic?</li>
</ul>
<p>Serious or potentially life-threatening reductions in blood flow to the brain or extremities have been reported rarely due to interactions between dihydroergotamine mesylate, USP nasal spray and protease inhibitors or  macrolide antibiotics.</p>
<p><span class="Bold">REMEMBER TO TELL YOUR DOCTOR IF YOU HAVE ANSWERED YES TO ANY OF THESE QUESTIONS BEFORE YOU USE dihydroergotamine mesylate, USP nasal spray.</span></p>
<p><span class="Bold Italics">Side Effects To Watch Out For</span></p>
<p>In clinical trials, most <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients have used Migranal<span class="Sup">®</span> (dihydroergotamine mesylate, USP) Nasal Spray without serious side effects. You may experience some <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> or irritation, altered sense of taste, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> after using dihydroergotamine mesylate, USP nasal spray. These side effects are temporary and usually do not require you to stop using dihydroergotamine mesylate, USP nasal spray. Although the following reactions rarely occur, they can be serious and should be reported to your  physician immediately:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your fingers and toes</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, tightness, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your chest</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> in your arms and legs</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> in your legs</li>
<li>Temporary speeding or slowing of your heart rate</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul>
<p><span class="Bold Italics">Dosing Information</span></p>
<ul>
<li>Each vial contains one complete dose of dihydroergotamine mesylate, USP nasal spray, which is 1 spray in each nostril followed in 15 minutes by an additional spray in each nostril, for a total of 4 sprays.</li>
<li>Studies have shown no benefit from acute doses greater than 2.0 mg (4 sprays) for a single administration. The safety of doses greater than 3.0 mg in a 24 hour period has not been established.</li>
<li>The safety of doses greater than 4.0 mg in a 7-day period has not been established.</li>
<li>Dihydroergotamine mesylate, USP nasal spray, should not be used for chronic daily administration.</li>
</ul>
<p><span class="Bold Italics">Learn what to do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>If you have used more medication than you have been instructed, contact your doctor, hospital emergency department, or nearest poison control center immediately.</p>
<p><span class="Bold">How to use the dihydroergotamine mesylate, USP nasal spray</span></p>
<dl>
<dt>1.</dt>
<dd>Use available training materials. 								<ul class="Disc">
<li>Read and follow the instructions in the administration instructions which are provided with the dihydroergotamine mesylate, USP nasal spray package before attempting to use the product.</li>
<li>If there are any questions concerning the use of your dihydroergotamine mesylate, USP nasal spray, ask your doctor or pharmacist.</li>
</ul>
</dd>
<dt>2.</dt>
<dd>Check the contents of the package: 							 								<ul>
<li>8 Nasal Spray Vials</li>
<li>8 Nasal Sprayers</li>
<li>Administration Instructions</li>
<li>Package Insert</li>
</ul>
</dd>
<dt>3.</dt>
<dd>Assemble the sprayer:<br><span class="Bold">Assemble your nasal sprayer only when you are ready to use it.</span>
</dd>
</dl>
<dl>
<dd><ul class="Disc">
<li>Lift tab to bend back blue cover. In one piece, completely remove the blue cover and metal seal in a circular motion. Keeping the vial upright, remove rubber stopper. Set vial aside.</li>
<li>Remove plastic cover from the bottom of pump unit. Insert spray pump into vial and turn clockwise until securely fastened.</li>
</ul></dd>
<dt>4.</dt>
<dd>Using the sprayer: 							 							<ul class="Disc">
<li>Remove cap from spray unit. Holding the vial upright, point nasal sprayer away from face and pump 4 times before using. DO NOT PUMP MORE THAN 4 TIMES. (Although some medication will spray out, there is enough medication in each vial to allow you to prepare your nasal spray pump properly and still receive a full treatment of dihydroergotamine mesylate, USP nasal spray.)</li>
<li>Spray once into each nostril. <span class="Underline">Do not tilt head back or sniff through your nose while spraying or immediately after</span>. Wait 15 minutes. Spray once again into each nostril.</li>
</ul>
</dd>
<dt>5.</dt>
<dd>After completing these instructions: 							<ul><li>Carefully dispose of the nasal spray pump with the vial.</li></ul>
</dd>
</dl>
<p><span class="Bold Italics">Important Notes:</span></p>
<ul><li>Once a dihydroergotamine mesylate, USP nasal spray vial has been opened, it must be thrown away after 8 hours.</li></ul>
<p><span class="Bold Italics">Storing dihydroergotamine mesylate, USP nasal spray</span></p>
<ul>
<li>Keep medication in a safe place away from children</li>
<li>Keep dihydroergotamine mesylate, USP nasal spray away from heat and light.</li>
<li>Do not expose dihydroergotamine mesylate, USP nasal spray to temperatures over 77°F.</li>
<li>Never refrigerate or freeze dihydroergotamine mesylate, USP nasal spray.</li>
<li>Do not keep an opened dihydroergotamine mesylate, USP nasal spray vial for more than 8 hours.<br><span class="Bold">Check the expiration date printed on the vial containing medication. If the expiration date has passed, do not use it.</span>
</li>
</ul>
<p><span class="Bold Italics">Answers to patients' questions about dihydroergotamine mesylate, USP nasal spray</span></p>
<p><span class="Bold">What if I need help in using my Migranal<span class="Sup">®</span>  (dihydroergotamine mesylate, USP) Nasal Spray?</span></p>
<p>If you have any questions or if you need help in opening, putting together, or using dihydroergotamine mesylate, USP nasal spray, speak to your doctor or pharmacist.</p>
<p><span class="Bold Italics">How much medication should I use and how often?</span></p>
<p>Each vial contains one complete dose of dihydroergotamine mesylate, USP nasal spray, which is 1 spray in each nostril, followed by an additional spray in each nostril 15 minutes later for a total of 4 sprays. Do not use more than this amount unless instructed to do so by your doctor. Dihydroergotamine mesylate, USP nasal spray is not intended for chronic daily use.</p>
<p><span class="Bold Italics">Why do I have to prime or pump the Nasal Sprayer 4 times before using? Am I <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span> the medication?</span></p>
<p>You have to prime the Nasal Sprayer 4 times to make sure that you get the proper amount of medication when you use it. Although you will see some medication spray out, there is still enough medication in each vial to allow you to prepare  your sprayer properly and still receive a full dose of dihydroergotamine mesylate, USP nasal spray.</p>
<p><span class="Bold Italics">Can I assemble the medication vial and the Nasal Sprayer so it is ready before I need to use it?</span></p>
<p>No. The brown (amber) glass vial containing your medication must remain unopened until you are ready to use it. It may not be fully effective if opened and not used within 8 hours.</p>
<p><span class="Bold Italics">Can I reuse my dihydroergotamine mesylate, USP nasal sprayer?</span></p>
<p>No. After completing the full dose, you must carefully dispose of your dihydroergotamine mesylate, USP nasal spray and the opened vial. You should use a new unit for your next <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Each Unit contains a new Nasal Sprayer, and a vial of dihydroergotamine mesylate, USP nasal spray medication.</p>
<p><span class="Bold Italics">Can I use dihydroergotamine mesylate, USP nasal spray if I have a stuffy nose, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, or allergies?</span></p>
<p>Yes. Dihydroergotamine mesylate, USP nasal spray can be used if you have a stuffy nose, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, or allergies. However, if you are taking any medications for your <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, or allergies, even those you can buy without a doctor's prescription, speak with your doctor before using dihydroergotamine mesylate, USP nasal spray.</p>
<p><span class="Bold Italics">Do I need to sniff the medication when I spray it in my nostril?</span></p>
<p>No, you should not sniff because dihydroergotamine mesylate, USP nasal spray should remain in the nose so that it can be absorbed into the bloodstream through the lining of the nose. If you have any other unanswered questions about dihydroergotamine mesylate, USP nasal spray, consult your doctor or pharmacist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First">All trademarks are the trademarks or the registered trademarks of their respective owners.</p>
<p>Manufactured by:<br>MiPharm S.p.A<br>Milan, Italy</p>
<p>Distributed by:<br>Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807</p>
<p>Rev. 01/13<br>USA/932599</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 4 mg/mL Vial Label</h1>
<p class="First"><span class="Bold">NDC</span> 68682-357-10<br>Rx only</p>
<p><span class="Bold">Dihydroergotamine Mesylate, USP</span><br><span class="Bold">NASAL SPRAY</span></p>
<p>4 mg/mL (1 mL/vial)<br>1 mL contains 4 mg dihydroergotamine mesylate, USP</p>
<p>FOR NASAL USE ONLY<br>NOT FOR INJECTION</p>
<p><span class="Bold">Manufactured by:</span> Mipharm S.p.A., Milan, Italy</p>
<p><span class="Bold">Distributed by:</span> Oceanside Pharmaceuticals,<br>a division of Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807</p>
<p>Made in Italy<br>USA/920889<br>Rev. 01/13</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 4 mg/mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc&amp;name=migranal-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIHYDROERGOTAMINE MESYLATE 		
					</strong><br><span class="contentTableReg">dihydroergotamine mesylate spray</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68682-357</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">NASAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dihydroergotamine mesylate</strong> (dihydroergotamine) </td>
<td class="formItem">dihydroergotamine mesylate</td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Caffeine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Anhydrous Dextrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon Dioxide</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68682-357-10</td>
<td class="formItem">8  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA020148</td>
<td class="formItem">03/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Oceanside Pharmaceuticals
							(832011691)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MIPHARM SPA</td>
<td class="formItem"></td>
<td class="formItem">514042399</td>
<td class="formItem">MANUFACTURE(68682-357)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>977de209-c53a-4cb4-9f3f-1e850600a9dc</div>
<div>Set id: 977de209-c53a-4cb4-9f3f-1e850600a9dc</div>
<div>Version: 1</div>
<div>Effective Time: 20130318</div>
</div>
</div> <div class="DistributorName">Oceanside Pharmaceuticals</div></p>
</body></html>
